Bristol Myers Sells 60% Holding in China Partnership Deal
Bristol Myers Squibb has taken another significant step in reshaping its global strategy. The company has officially announced the sale of its 60% stake in a long-standing China partnership. This move has attracted the attention of global investors, stock market analysts, and healthcare industry experts who are closely tracking the changing dynamics of pharmaceutical expansion in Asia.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
